MASH
MASH
Search
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Mental Health and the Value of Connection
Mental Health and the Value of Connection
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
cardiometabolic-infographic.pdf
cardio-metabolic.pdf
Patient-centric cardio-renal-metabolic disease research at Boehringer Ingelheim
CardioMetabolic_infographic_Update_2021.pdf
Partnering Interests in CardioMetabolic Diseases
Partnering Interests in CardioMetabolic Diseases
partnering-cardiometabolic_0.pdf
partnering-cardiometabolic.pdf
AH-Partnering-Cardiometabolic-Diseases.pdf
Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US
Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.
Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US
BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
Jardiance® (empagliflozin) analysis reinforces established safety profile
Jardiance® (empagliflozin) analysis reinforces established safety profile
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
FDA approves treatment option for T2D in children 10 and older
FDA has approved Jardiance® (empagliflozin) tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes. See Safety, PI & Med Guide.
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.